We're impressed with Conshohocken, PA-based CardioNet (NASDAQ: BEAT):
CardioNet has developed an integrated technology and service–mobile cardiac outpatient telemetry (MCOT)—which enables heartbeat-by-heartbeat, ECG monitoring, analysis and response, at home or away, 24/7/365.
CardioNet is focused on helping physicians diagnose and treat patients with arrhythmias. Time is of the essence in diagnosing and treating arrhythmias. Delays can lead to increased morbidity and mortality and cause significant anxiety for patients. But rapidly diagnosing and effectively treating patients with arrhythmia can be challenging. Some arrhythmias occur too infrequently to be detected through 24-48 hours of Holter monitoring. Event recorders pose problems with asymptomatic patients and those who have difficulty triggering monitoring equipment. Correlating events with symptoms is often difficult. CardioNet offers physicians a powerful diagnostic and patient management tool to address these challenges.
MarketIntellNow Notes--
- Market Opportunity: digital home health is growing fast off a small base
- Product Line: well-crafted for both docs & patients with one small study so far
- Positioning/Competition: competitive set includes behemoth Philips Healthcare
- IP: 24 current patents
- Financial Strength: 65% annual revenue growth in '08
- Selling Horsepower: Strong in the US with 88 account reps covering 49 states.
SUMMARY: Companies moving what were once hospital-based services to the home can prosper if they navigate the shoals of IP, reimbursement et al. It's worth noting that CardioNet has product muscle ... and selling muscle. It has direct account reps in 49 of 50 states, flooding the zone in the USA before being lured to foreign shores where players like Dutch giant Philips are well-established and reimbursement methods are far different.NOTE: Add us on twitter-- we're www.twitter.com/marketintellnow
